EPM2A Antikörper (AA 101-199)

Produktnummer ABIN563505

Produktdetails anti-EPM2A Antikörper

Target: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Bindungsspezifität: AA 101-199

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser EPM2A Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Verwendungszweck: Mouse monoclonal antibody raised against a partial recombinant EPM2A.

Sequenz: GNGPHHDRCC TYNENNLVDG VYCLPIGHWI EATGHTNEMK HTTDFYFNIA GHQAMHYSRI LPNIWLGSCP RQVEHVTIKL KHELGITAVM NFQTEWDIV

Kreuzreaktivität: Human, Ratte

Produktmerkmale: Antibody Reactive Against Recombinant Protein.

Immunogen: EPM2A (NP_001018051, 101 a.a. ~ 199 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Klon: 6C6

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: In 1x PBS, pH 7.4

Handhabung: Aliquot to avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Referenzen für anti-EPM2A Antikörper (ABIN563505)

Irimia, Tagliabracci, Meyer, Segvich, DePaoli-Roach, Roach: "Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice." in: The Journal of biological chemistry, (2015) (PubMed).

Zhu, Zhang, Kelly, Cheng: "The carbohydrate-binding domain of overexpressed STBD1 is important for its stability and protein-protein interactions." in: Bioscience reports, Vol. 34, Issue 4, (2014) (PubMed).

Sherwood, Johnson, Delgado-Escueta, Gentry: "A bioassay for Lafora disease and laforin glucan phosphatase activity." in: Clinical biochemistry, Vol. 46, Issue 18, pp. 1869-76, (2013) (PubMed).

DePaoli-Roach, Segvich, Meyer, Rahimi, Worby, Gentry, Roach: "Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity." in: Human molecular genetics, Vol. 21, Issue 7, pp. 1604-10, (2012) (PubMed).

Tiberia, Turnbull, Wang, Ruggieri, Zhao, Pencea, Israelian, Wang, Ackerley, Wang, Liu, Minassian: "Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease." in: The Journal of biological chemistry, Vol. 287, Issue 30, pp. 25650-9, (2012) (PubMed).

Turnbull, Girard, Lohi, Chan, Wang, Tiberia, Omer, Ahmed, Bennett, Chakrabarty, Tyagi, Liu, Pencea, Zhao, Scherer, Ackerley, Minassian: "Early-onset Lafora body disease." in: Brain : a journal of neurology, Vol. 135, Issue Pt 9, pp. 2684-98, (2012) (PubMed).

Turnbull, Wang, Girard, Ruggieri, Wang, Draginov, Kameka, Pencea, Zhao, Ackerley, Minassian: "Glycogen hyperphosphorylation underlies lafora body formation." in: Annals of neurology, Vol. 68, Issue 6, pp. 925-33, (2011) (PubMed).

Tagliabracci, Turnbull, Wang, Girard, Zhao, Skurat, Delgado-Escueta, Minassian, Depaoli-Roach, Roach: "Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 49, pp. 19262-6, (2007) (PubMed).

Details zu EPM2A

Target: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Andere Bezeichnung: EPM2A (EPM2A Produkte)

Synonyme: TG-B antikoerper, Tg(TcraK,TcrbK)TG-BFlv antikoerper, EPM2 antikoerper, MELF antikoerper, laforin antikoerper, EPM2A, laforin glucan phosphatase antikoerper, epilepsy, progressive myoclonic epilepsy, type 2 gene alpha antikoerper, EPM2A antikoerper, Epm2a antikoerper

Hintergrund: Full Gene Name: epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)
Synonyms: EPM2,MELF

Gen-ID: 7957

NCBI Accession: NM_001018041

Pathways: Cellular Glucan Metabolic Process